Loading patent…
AssigneeZymedi Co., Ltd.
InventorsNam Hoon Kwon, Jin Young Lee, Sunghoon Kim
Estimating the term…
The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthetase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthetase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.
A pharmaceutical composition comprising an antibody biding specifically to an epitope contaiing the sequence of SEQ ID NO:
Use of an antibody or functional fragments thereof specifically binding to an epitope containing the sequence of SEQ ID NO:
A method for treating immune cell migration-related diseases in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising an antibody biding specifically to an epitope containing the sequence of SEQ ID NO:
Dependencies are inferred from the claim text.